Evidence map›Paper›PMID 40022573›Full record

ArticleCancer medicine2025

Utility of a Large Series of B-Cell Precursor Acute Lymphoblastic Leukemia Cell Lines as a Model System.

Minori Tamai, Chiaki Komatsu, Keiko Kagami, Shin Kasai, Koshi Akahane, Kumiko Goi, Kanji Sugita, Chihiro Tomoyasu, Toshihiko Imamura, Hiroaki Goto and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Minori TamaiGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.ORCID https://orcid.org/0000-0001-6905-4582
Chiaki KomatsuGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.
Keiko KagamiGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.
Shin KasaiDepartment of Pediatrics, University of Yamanashi, Yamanashi, Japan.
Koshi AkahaneGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.ORCID https://orcid.org/0000-0001-8591-1281
Kumiko GoiGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.
Kanji SugitaGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.
Chihiro TomoyasuDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroaki GotoHematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan.
Takeshi InukaiGlobal Leukemia Cell-Line Assembly Network, University of Yamanashi, Yamanashi, Japan.ORCID https://orcid.org/0000-0002-4783-2184

Funding

Japan Research Foundation for Clinical PharmacologyJapan Society for the Promotion of Science 23K24298
6 · The paper itself

Abstract

backgroundIn B-cell precursor acute lymphoblastic leukemia (BCP-ALL), chromosomal translocations are strongly associated with prognoses. RNA sequencing (RNA-seq) is a powerful technology that reveals a close correlation between types of translocation and patterns of gene expression in clinical samples of BCP-ALL. Cancer cell lines are powerful research tools, and thus, we built a larger series of BCP-ALL cell lines and performed RNA-seq analysis to confirm their utility as a model system.

methodsWe performed RNA-seq in a total of 94 BCP-ALL cell lines, including 80 cell lines with 8 representative types of translocations.

resultsIn the UMAP visualization, a close association was confirmed between the types of fusion genes and patterns of gene expression. In the cluster analysis of the gene expression profile, each type of fusion gene showed a clear association with the expression profile in the top 51 variable genes. Of clinical importance, the majority of the top variable genes in the BCP-ALL cell lines also showed a significant association with the types of fusion genes in the clinical samples. When an association of 125 cell cycle-related genes with the percentage of S and G2/M phases in 67 cell lines was evaluated, a significant positive correlation with cell cycle progression was confirmed in 10 cell cycle-related genes (HDAC2, CDC23, YWHAG, MAD2L1, CCNH, ANAPC7, CDC6, ANAPC5, ORC3, andRBX1). Moreover, significant upregulation and downregulation of 40 and 10 genes, respectively, were observed in the cell lines established at relapse compared with those established at diagnosis. Four (SP6, CCNE1, HIST1H2BH, and DECR2) and two (EVI2B and SYN1) of these genes were also significantly higher and lower, respectively, in the clinical samples at relapse than in those at diagnosis.

conclusionLarge series of BCP-ALL cell lines is a powerful research tool for studying the mechanisms of leukemogenesis and the disease progression of BCP-ALL.

Indexed as

Precursor B-Cell Lymphoblastic Leukemia-LymphomaCell CycleCell Line, TumorGene Expression ProfilingGene Expression Regulation, LeukemicHumansOncogene Proteins, FusionRNA-SeqTranscriptomeTranslocation, GeneticOncogene Proteins, FusionBCP‐ALLcell cyclechemoresistanceleukemogenesisrelapseRNA‐seq

Identifiers

PMID40022573
PMCPMC11871424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.